Where does Dyne Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$451.71M-1.2%	-$446.21M-5.3%	-$423.8M-2.6%	-$412.89M-12.5%	-$367.13M-15.7%
Depreciation and amortization	$2.07M+2.4%	$2.02M+3.6%	$1.95M+5.4%	$1.85M+5.7%	$1.75M+7.1%
Stock-based compensation	$45.91M+0.1%	$45.85M+1.7%	$45.1M+5.5%	$42.77M+9.7%	$38.98M-15.0%
Net cash from operating activities	-$442.24M-9.7%	-$403.21M-7.3%	-$375.71M-4.5%	-$359.56M-12.5%	-$319.73M-9.4%
Capital expenditures	$1.16M-39.6%	$1.92M-23.5%	$2.51M+6.0%	$2.37M-25.2%	$3.17M+33.2%
Net cash from investing activities	-$33.58M-12.9%	-$29.73M+35.0%	-$45.74M-68.3%	-$27.18M+19.9%	-$33.96M+84.2%
Proceeds from issuance of debt	——	——	——	——	——
Net cash from financing activities	$756.13M-15.1%	$890.31M+92.3%	$462.98M+75.6%	$263.66M-51.4%	$542.75M-33.0%
Net increase (decrease) in cash	$281.29M-38.6%	$458.35M—	——	——	——
Free cash flow	-$443.4M-9.4%	-$405.13M-7.1%	-$378.22M-4.5%	-$361.93M-12.1%	-$322.89M-9.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dyne Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.